Novavax (NVAX) Preferred Stock Liabilities (2020)
Novavax (NVAX) recorded quarterly Preferred Stock Liabilities of $199.8 million in Q3 2020, little changed quarter-over-quarter from $199.8 million in Q2 2020.
Novavax (NVAX) Preferred Stock Liabilities (2020) Analysis & Trends
Novavax's Preferred Stock Liabilities history runs 1 years deep, the most recent figure standing at $199.8 million for Q3 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Novavax | 1.49 Bn | 931.98 Mn | 108.82 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2020 | 199.82 Mn |
| Jun 30, 2020 | 199.82 Mn |